Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Wollin, I. Maillet, V. Quesniaux, B. Ryffel (Biberach, Germany; Orleans, France). Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice. Eur Respir J 2013; 42: Suppl. 57, 682

Member's Comments

No comment yet.

Related content which might interest you: Olodaterol attenuates bleomycin induced lung fibrosis in mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 The immunomodulatory effect of protein S in pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases Year: 2013 A transient receptor potential melastin-2 deficiency significantly worsens the fibrotic response to bleomycin in mice Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Does Rosemary leaves extract can attenuate lung injury in experimental pulmonary fibrosis in rats? Source: International Congress 2016 – ILD pathogenesis Year: 2016 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice via decreasing MCP-1 mRNA Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice Source: International Congress 2016 – ILD pathogenesis Year: 2016 Novel biomarkers in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013